Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S.

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 202 ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

Neoplastic Agents Market Report 2025" has been added to ResearchAndMarkets.com's offering.This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, ...

Multinational pharmaceutical firms, particularly U.S. giants, are increasingly recognizing China's burgeoning innovative drug sector as a strategic goldmine to bolster their global competitiveness.

BEIJING, March 27 (Xinhua) -- Multinational pharmaceutical firms, particularly U.S. giants, are increasingly recognizing China's burgeoning innovative drug sector as a strategic goldmine to bolster ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, named its new Board of Directors led by co-founder Jérôme Koch, in line with recent bridge financing organized ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended formA hearing on infringement of EP 3 ...